Overview

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer. The study will look at safety of the study drug and whether the treatment schedule is tolerated by patients.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmacyclics LLC.
Treatments:
Abexinostat